Cart (0 Items)
Your cart is currently empty.
View Products
| size | 100ug |
|---|---|
| Brand | ProteoGenix |
| Product type | Recombinant Proteins |
| Host Species | Escherichia coli (E. coli) |
| Applications | Elisa, WB |
| Product name | CD274 / PD-L1 / B7-H1, N-His, recombinant protein |
|---|---|
| Origin species | Homo sapiens (Human) |
| Expression system | Prokaryotic expression |
| Molecular weight | 27.50 kDa |
| Protein delivered with Tag? | N-terminal His Tag |
| Purity estimated | >90% as determined by SDS-PAGE |
| Buffer | PBS, pH7.5 |
| Delivery condition | Dry Ice |
| Storage condition | 4°C for short term (1 week), -20°C or -80°C for long term (avoid freezing/thawing cycles; addition of 20-40% glycerol improves cryoprotection) |
| Brand | ProteoGenix |
| Host species | Escherichia coli (E.coli) |
| Fragment Type | Phe19-Arg238 |
| Protein Accession | Q9NZQ7 |
| Reference | PX-P5608 |
| Note | For research use only |
CD274 / PD-L1 / B7-H1 is a type I transmembrane protein that is expressed on the surface of various cells, including antigen-presenting cells. It is composed of a single extracellular immunoglobulin-like domain, a transmembrane domain, and a short cytoplasmic tail.
CD274 / PD-L1 / B7-H1 is an inhibitory receptor that binds to its ligand, programmed cell death-1 (PD-1), expressed on the surface of activated T cells. This interaction suppresses T cell activation and proliferation, and promotes the induction of tolerance.
CD274 / PD-L1 / B7-H1 is involved in the regulation of immune responses and is a target for immunotherapy. The use of monoclonal antibodies to block the interaction between CD274 / PD-L1 / B7-H1 and PD-1 has been shown to enhance anti-tumor immunity, leading to improved clinical outcomes in cancer patients.
CD274 / PD-L1 / B7-H1, N-His, recombinant protein on SDS-PAGE under reducing condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is superior than 90 %
Send us a message from the form below
Reviews
There are no reviews yet.